Cryosite Limited (ASX:CTE)
Australia · Delayed Price · Currency is AUD 1.170
-0.010 (-0.85%)
Sep 17, 2026, 4:10 PM AEST
Cryosite Revenue
In the fiscal year ending June 30, 2026, Cryosite had annual revenue of 16.70M AUD with 18.31% growth. Cryosite had revenue of 8.43M in the half year ending June 30, 2026, with 35.70% growth.
Revenue
16.70M
Revenue Growth
+18.31%
P/S Ratio
3.45
Revenue / Employee
618.52K
Employees
27
Market Cap
57.60M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 16.70M | 2.58M | 18.31% |
| Jun 30, 2025 | 14.12M | 1.50M | 11.93% |
| Jun 30, 2024 | 12.61M | 677.00K | 5.67% |
| Jun 30, 2023 | 11.94M | 178.00K | 1.51% |
| Jun 30, 2022 | 11.76M | 1.73M | 17.29% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Healius | 1.37B |
| Australian Clinical Labs | 736.15M |
| Monash IVF Group | 269.46M |
| ImExHS | 31.27M |
| Genetic Signatures | 19.33M |
| Microba Life Sciences | 14.76M |
| BCAL Diagnostics | 2.35M |
| INOVIQ | 2.21M |